AH
Unclaimed author profile

Ahmed Abdelalim

· Baqiyatallah University of Medical Sciences

Is this your research profile?

Create or sign in to your KnowledgeTrend account to claim this page. After the claim, this same profile URL and its linked publications will belong to your account. Claiming does not automatically grant a verified badge.

Create account and claim this profile Sign in to claim
2Linked publications
0Citations
0h-index
0i10-index

Metrics are calculated from publications currently linked to this profile.

Researcher overview

About

Ahmed Abdelalim is a registered researcher in their academic field.

Research output

Recent Publications

2 research works linked to this profile

▤
Global Cancer Incidence and Screening, COVID-19 and healthcare impacts, Hematological disorders and diagnostics · 2019 · JAMA Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

Christina Fitzmaurice, Degu Abate, Naghmeh Abbasi, Hedayat Abbastabar, Foad Abd-Allah, Omar Abdel‐Rahman, Ahmed Abdelalim, Amir Abdoli, Ibrahim Abdollahpour, Abdishakur S. M. Abdulle, Nebiyu Dereje Abebe, Haftom Niguse Abraha, Laith J. Abu‐Raddad, Ahmed Abualhasan, Isaac Akinkunmi Adedeji, Shailesh M Advani, Mohsen Afarideh, Mahdi Afshari, Mohammad Aghaali, Dominic Agius, Sutapa Agrawal, Ayat Ahmadi, Elham Ahmadian, Ehsan Ahmadpour, Muktar Beshir Ahmed, Mohammad Esmaeil Akbari, Tomi Akinyemiju, Ziyad Al‐Aly, Assim M. AlAbdulKader, Fares Alahdab, Shazia Alam, Genet Melak Alamene, Birhan Alemnew, Kefyalew Addis Alene, Cyrus Alinia, Vahid Alipour, Syed Mohamed Aljunid, Fatemeh Allah Bakeshei, Majid A. Almadi, Amir Almasi‐Hashiani, Ubai Alsharif, Shirina Alsowaidi, Nelson Alvis‐Guzmán, Erfan Amini, Saeed Amini, Yaw Ampem Amoako, Zohreh Anbari, Nahla Anber, Cătălina Liliana Andrei, Mina Anjomshoa, Fereshteh Ansari, Ansariadi Ansariadi, Seth Christopher Yaw Appiah, Morteza Arab‐Zozani, Jalal Arabloo, Zohreh Arefi, Olatunde Aremu, Habtamu Abera Areri, Al Artaman, Hamid Asayesh, Ephrem Tsegay Asfaw, Alebachew Fasil Ashagre, Reza Assadi, Bahar Ataeinia, Hagos Tasew Atalay, Zerihun Ataro, Suleman Atique, Marcel Ausloos, Leticia Ávila‐Burgos, Euripide Avokpaho, Ashish Awasthi, Nefsu Awoke, Beatriz Paulina Ayala Quintanilla, Martin Amogre Ayanore, Henok Tadesse Ayele, Ebrahim Babaee, Umar Bacha, Alaa Badawi, Mojtaba Bagherzadeh, Eleni Bagli, Senthilkumar Balakrishnan, Abbas Balouchi, Till Bärnighausen, Robert J. Battista, Masoud Behzadifar, Meysam Behzadifar, Bayu Begashaw Bekele, Yared Belete Belay, Yaschilal Muche Belayneh, Kathleen Berfield, Adugnaw Berhane, Eduardo Bernabé, Mircea Beuran, Nickhill Bhakta, Krittika Bhattacharyya, Belete Biadgo, Ali Bijani, Muhammad Shahdaat Bin Sayeed, Charles Birungi, Catherine Bisignano

Importance Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs). Conclusions and Relevance The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.

▤
Parkinson's Disease Mechanisms and Treatments, Voice and Speech Disorders, Cerebral Palsy and Movement Disorders · 2018 · The Lancet Neurology

Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

BACKGROUND: Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. METHODS: Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. FINDINGS: In 2016, 6·1 million (95% uncertainty interval [UI] 5·0-7·3) individuals had Parkinson's disease globally, compared with 2·5 million (2·0-3·0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21·7% (95% UI 18·1-25·3) over the same period (compared with an increase of 74·3%, 95% UI 69·2-79·6, for crude prevalence rates). Parkinson's disease caused 3·2 million (95% UI 2·6-4·0) DALYs and 211 296 deaths (95% UI 167 771-265 160) in 2016. The male-to-female ratios of age-standardised prevalence rates were similar in 2016 (1·40, 95% UI 1·36-1·43) and 1990 (1·37, 1·34-1·40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. INTERPRETATION: Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially. FUNDING: Bill & Melinda Gates Foundation.